Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.

Veeraputhiran M, Jain T, Cronin S, Al-Kadhimi Z, Abidi MH, Ayash L, Mellert K, Lum LG, Ratanatharathorn V, Uberti JP, Deol A.

J Clin Apher. 2014 Dec;29(6):293-8. doi: 10.1002/jca.21321. Epub 2014 Apr 3.

PMID:
24700728
[PubMed - in process]
2.

Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.

Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T, Lilleby K, Storb R, Bensinger WI.

Bone Marrow Transplant. 1996 Jun;17(6):937-41.

PMID:
8807097
[PubMed - indexed for MEDLINE]
3.

Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.

Koç ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, Fox RM, Szekely EM, Tainer N, Lazarus HM.

J Clin Oncol. 2000 May;18(9):1824-30.

PMID:
10784622
[PubMed - indexed for MEDLINE]
4.

Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.

Alexander ET, Towery JA, Miller AN, Kramer C, Hogan KR, Squires JE, Stuart RK, Costa LJ.

Transfusion. 2011 Sep;51(9):1995-2000. doi: 10.1111/j.1537-2995.2011.03085.x. Epub 2011 Mar 10.

PMID:
21392017
[PubMed - indexed for MEDLINE]
5.

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF.

Biol Blood Marrow Transplant. 2008 Sep;14(9):1045-56. doi: 10.1016/j.bbmt.2008.07.004.

PMID:
18721768
[PubMed - indexed for MEDLINE]
6.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.

PMID:
22683613
[PubMed - indexed for MEDLINE]
7.

Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.

Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, Silva M, Steinberg M, Matous J, Selvey S, Maris M, McSweeney PA.

Biol Blood Marrow Transplant. 2011 May;17(5):729-36. doi: 10.1016/j.bbmt.2010.08.018. Epub 2010 Oct 14.

PMID:
20813198
[PubMed - indexed for MEDLINE]
8.

A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor.

Abhyankar S, DeJarnette S, Aljitawi O, Ganguly S, Merkel D, McGuirk J.

Bone Marrow Transplant. 2012 Apr;47(4):483-7. doi: 10.1038/bmt.2011.133. Epub 2011 Jul 4.

PMID:
21725372
[PubMed - indexed for MEDLINE]
9.

Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization.

Gazitt Y, Freytes CO, Callander N, Tsai TW, Alsina M, Anderson J, Holle L, Cruz J, Devore P, McGrath M, West G, Alvarez R, Montgomery W.

J Hematother. 1999 Apr;8(2):173-83.

PMID:
10349911
[PubMed - indexed for MEDLINE]
10.

Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.

Bellido M, Sureda A, Martino R, Madoz P, García J, Brunet S.

Haematologica. 1998 May;83(5):428-31.

PMID:
9658727
[PubMed - indexed for MEDLINE]
Free Article
11.
12.

Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.

Keating GM.

Drugs. 2011 Aug 20;71(12):1623-47. doi: 10.2165/11206040-000000000-00000. Review.

PMID:
21861545
[PubMed - indexed for MEDLINE]
13.

Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.

Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.

Biol Blood Marrow Transplant. 2004 Jun;10(6):395-404.

PMID:
15148493
[PubMed - indexed for MEDLINE]
14.

Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.

Kosmas C, Athanasopoulos A, Dimitriadis G, Miltiadous C, Zilakos M, Lydakis D, Magiorkinis E, Gekas C, Daladimos T, Mylonakis N, Ziras N.

Anticancer Drugs. 2014 Aug;25(7):841-7. doi: 10.1097/CAD.0000000000000100.

PMID:
24625457
[PubMed - in process]
15.

Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.

Gómez-Espuch J, Moraleda JM, Ortuño F, Lozano ML, Ayala F, Vallejo C, de Arriba F, Vicente V.

Bone Marrow Transplant. 2000 Feb;25(3):231-5.

PMID:
10673692
[PubMed - indexed for MEDLINE]
Free Article
16.

Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent.

Yuan S, Nademanee A, Krishnan A, Kogut N, Shayani S, Wang S.

Transfusion. 2013 Dec;53(12):3244-50. doi: 10.1111/trf.12198. Epub 2013 Apr 22.

PMID:
23607889
[PubMed - indexed for MEDLINE]
17.

Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.

Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Färber L, Burger KJ, Goldschmidt H, Hoelzer D, Haas R.

Bone Marrow Transplant. 1998 Oct;22(7):625-30.

PMID:
9818688
[PubMed - indexed for MEDLINE]
Free Article
18.

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.

Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio J.

Biol Blood Marrow Transplant. 2008 Nov;14(11):1253-61. doi: 10.1016/j.bbmt.2008.08.011.

PMID:
18940680
[PubMed - indexed for MEDLINE]
19.

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.

Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G.

Biol Blood Marrow Transplant. 2009 Feb;15(2):249-56. doi: 10.1016/j.bbmt.2008.11.028.

PMID:
19167685
[PubMed - indexed for MEDLINE]
20.

Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.

Hundemer M, Engelhardt M, Bruckner T, Kraeker S, Schmitt A, Sauer S, Neben K, Witzens-Harig M, Goldschmidt H, Ho AD, Wuchter P.

J Clin Apher. 2014 Dec;29(6):299-304. doi: 10.1002/jca.21323. Epub 2014 Apr 26.

PMID:
24771277
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk